GSK will award $500,000 in research grants for innovative HIV/AIDS drug research in recognition of the need to produce new alternatives and hope in the fight against the HIV/AIDS pandemic. The one-time research grants range from $25,000 to $150,000 and are intended to further the development of inventive treatments for HIV/AIDS, including therapies aimed at treating infection, prophylactic vaccines, or microbicides designed to prevent transmission of the virus.
For detailed information about the GSK Drug Discovery and Development Research Grant Program, as well as an application, please call 1-888-527-6935 or visit www.dddresearchgrant.com.
Since the inception of the Drug Discovery and Development Research Grant Program in 2001, GSK has honored nine researchers for their groundbreaking work toward new pharmaceutical strategies to combat the HIV virus.
Research grant recipients will be announced in September 2003 at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago. The grants will be paid Nov. 1, 2003.
GlaxoSmithKline is a pharmaceutical industry leader in HIV research and therapies. The company is engaged in basic research programs designed to investigate new targets to treat HIV. In addition to GlaxoSmithKlines Drug Discovery and Development Research Grant Program, the company also provides grants to community based organizations that provide services to those whose lives are most affected by HIV.